Difference between revisions of "Elacestrant (Orserdu)"
Jump to navigation
Jump to search
m |
m |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
==Diseases for which it is established== | ==Diseases for which it is established== | ||
| − | + | *[[Breast cancer, ER-positive]] | |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2023-01-27: Approved for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic [[breast cancer]] with disease progression following at least one line of endocrine therapy. ''(Based on EMERALD)'' |
| + | ==History of changes in EMA indication== | ||
| + | *2023-09-20: Initial marketing authorization as Orserdu. Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic [[breast cancer]] with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' RAD-1901 |
*'''Brand name:''' Orserdu | *'''Brand name:''' Orserdu | ||
| Line 14: | Line 16: | ||
[[Category:Intramuscular medications]] | [[Category:Intramuscular medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:Estrogen receptor inhibitors]] | [[Category:Estrogen receptor inhibitors]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:FDA approved in 2023]] | [[Category:FDA approved in 2023]] | ||
| + | [[Category:EMA approved in 2023]] | ||
Latest revision as of 12:24, 1 October 2023
Mechanism of action
From the NCI Drug Dictionary: An orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Upon oral administration of higher doses of elacestrant, this agent acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells. At lower doses of this agent, RAD1901 acts as a SERM and has estrogen-like effects in certain tissues, which can both reduce hot flashes and protect against bone loss. In addition, elacestrant is able to cross the blood-brain barrier (BBB).
Diseases for which it is established
History of changes in FDA indication
- 2023-01-27: Approved for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. (Based on EMERALD)
History of changes in EMA indication
- 2023-09-20: Initial marketing authorization as Orserdu. Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
Also known as
- Code name: RAD-1901
- Brand name: Orserdu